This trial is evaluating whether Fostamatinib will improve 1 primary outcome in patients with Leukemia. Measurement will happen over the course of through study completion, an average of 1 year.
This trial requires 20 total participants across 1 different treatment group
This trial involves a single treatment. Fostamatinib is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 1 and are in the first stage of evaluation with people.
"Results from a recent paper show that the most common side effects were mild (although frequent) gastrointestinal disturbances such as diarrhoea, nausea and vomiting, but these were only moderate in severity and did not impede treatment. In addition, only a small proportion of patients had haematological toxicity. The most serious adverse reactions were anaemia and leucopenia. All the patients took the drug as prescribed at the doses used In a recent study, and therefore the conclusions drawn from this study cannot be extrapolated to other patients taking the drug." - Anonymous Online Contributor
"In this population-based cohort, there were approximately 1.8 new cases per 100 000 persons per year (95% CI, 1.1-2.9) with MDS; one-third of these were <60 years old. The sex ratio was slightly higher than expected (p<0.05); women had a 2-fold increase in risk of developing MDS compared with men." - Anonymous Online Contributor
"As of now, treatments for MDS have explored several avenues. One avenue involves targeting aberrant pathways common to both normal and malignant cells; another avenue involves the use of immunomodulators to restore normal immune function and thereby treat MDS. There is also work being done using therapies that aim to repair dysfunctional DNA or RNA. Still other avenues involve targeting epigenetic changes such as promoter methylation or histone acetylation. In addition, strategies aimed at ensuring that the mutated protein is trafficked to the appropriate subcellular location (e.g., nuclear export) are being investigated. These studies highlight the need to develop novel agents to treat MDS." - Anonymous Online Contributor
"The current data suggest that the survival rate for patients with MDS with a <5% transfusion requirement is about 60%. However, patients with >5% transfusion need may experience a higher mortality rate." - Anonymous Online Contributor
"Myelodysplastic syndromes (MDS) appear to be a spectrum of diseases. The diagnostic criteria for MDS need to be revised and improved to better reflect the heterogeneity of the disease." - Anonymous Online Contributor
"There was little difference in most common side effects when comparing patients taking the same dose of fostamatinib who were enrolled in different clinical trials. Fostamatinib does not appear to have an effect on the frequency of serious adverse events. In patients with MDS, the rate of cytopenia was higher with the more frequent dosing schedule." - Anonymous Online Contributor
"MDS patients have abnormal blood cell counts even before they develop symptoms. These abnormalities can persist for many years and continue to worsen without treatment. Although MDS is rare, it is probably more common than people realize. Most cases occur after age 60, although there are exceptions. Approximately 10% of people with MDS die from complications related to their disorder. It is imperative that clinicians know how serious these disorders can get, because early diagnosis can help improve outcomes and reduce costs." - Anonymous Online Contributor
"There is a rapid progression of MDS in young adults; however, this is not true for older patients who have a slower disease progression. The survival rate for young adult patients is significantly lower than that for older patients, and the two ages groups should be treated differently." - Anonymous Online Contributor
"A couple of treatments are commonly used for MDS patients who have low-risk disease, including azacitidine (AZA), lenalidomide plus dexamethasone (RENATE), and thalidomide or pomalidomide alone. These treatments are generally effective, with response rates between 35-50%. Low-dose cytarabine has been shown to improve survival in MDS patients with high-risk features. The European Leukemia and Lymphoma Group recommends this agent for patients with transfusion dependence, elevated LDH serum levels, or who have FLT3 mutation." - Anonymous Online Contributor
"There is not enough evidence to recommend any specific therapy for MDS. Clinical trials may provide data for future therapies; however, large prospective trials are required to draw conclusions about safety and efficacy." - Anonymous Online Contributor